These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
85 related articles for article (PubMed ID: 18160582)
1. Soluble fibrin inhibits lymphocyte adherence and cytotoxicity against tumor cells: implications for cancer metastasis and immunotherapy. Biggerstaff JP; Weidow B; Dexheimer J; Warnes G; Vidosh J; Patel S; Newman M; Patel P Clin Appl Thromb Hemost; 2008 Apr; 14(2):193-202. PubMed ID: 18160582 [TBL] [Abstract][Full Text] [Related]
2. Lymphokine-activated killer cells can kill target cells not only by early killing but also by late killing, and the late killing level against autotumor cell line. Komatsu F; Ishiguro K Oncol Res; 2003; 13(4):235-41. PubMed ID: 12659424 [TBL] [Abstract][Full Text] [Related]
3. Soluble fibrin inhibits monocyte adherence and cytotoxicity against tumor cells: implications for cancer metastasis. Biggerstaff JP; Weidow B; Vidosh J; Dexheimer J; Patel S; Patel P Thromb J; 2006 Aug; 4():12. PubMed ID: 16925817 [TBL] [Abstract][Full Text] [Related]
4. Cancer cell cycle and adoptive immunotherapy using lymphokine-activated killer cells. Ejiri Y; Ohara M; Suzuki T; Kasukawa R Fukushima J Med Sci; 1997 Dec; 43(2):61-73. PubMed ID: 9640842 [TBL] [Abstract][Full Text] [Related]
5. [Comparative study on cytotoxicity of lymphocytes from different tissues in laryngeal cancer]. An W Zhonghua Er Bi Yan Hou Ke Za Zhi; 1993; 28(5):292-4, 314-5. PubMed ID: 8192933 [TBL] [Abstract][Full Text] [Related]
6. Adoptive immunotherapy for pancreatic cancer: cytotoxic T lymphocytes stimulated by the MUC1-expressing human pancreatic cancer cell line YPK-1. Kawaoka T; Oka M; Takashima M; Ueno T; Yamamoto K; Yahara N; Yoshino S; Hazama S Oncol Rep; 2008 Jul; 20(1):155-63. PubMed ID: 18575732 [TBL] [Abstract][Full Text] [Related]
7. Postoperative immunosuppression cascade and immunotherapy using lymphokine-activated killer cells for patients with esophageal cancer: possible application for compensatory anti-inflammatory response syndrome. Yamaguchi Y; Hihara J; Hironaka K; Ohshita A; Okita R; Okawaki M; Matsuura K; Nagamine I; Ikeda T; Ohara M; Hamai Y Oncol Rep; 2006 Apr; 15(4):895-901. PubMed ID: 16525677 [TBL] [Abstract][Full Text] [Related]
8. Tretinoin or retinol enhancement of lymphokine-activated killer cell proliferation and cytotoxicity against human bladder cancer cells in vitro. Wang ZP; Zheng RL; Chen YR; Liu GD Zhongguo Yao Li Xue Bao; 1997 Nov; 18(6):522-4. PubMed ID: 10322910 [TBL] [Abstract][Full Text] [Related]
9. Inhibition of lymphokine-activated killer cells generation in vitro by soluble factors released from mixed human tumor and peripheral blood mononuclear adherent cells culture. Eisenthal A; Barbarsteyn E; Gitstein G; Lifschitz-Mercer B Cancer Invest; 2006 Feb; 24(1):28-34. PubMed ID: 16466989 [TBL] [Abstract][Full Text] [Related]
10. Spermine-directed immunosuppression of cervical carcinoma cell sensitivity to a majority of lymphokine-activated killer lymphocyte cytotoxicity. Evans CH; Lee TS; Flugelman AA Nat Immun; 1995; 14(3):157-63. PubMed ID: 8832899 [TBL] [Abstract][Full Text] [Related]
11. Characterization of natural killer and natural killer-like T cells derived from ex vivo expanded and activated cord blood mononuclear cells: implications for adoptive cellular immunotherapy. Ayello J; van de Ven C; Cairo E; Hochberg J; Baxi L; Satwani P; Cairo MS Exp Hematol; 2009 Oct; 37(10):1216-29. PubMed ID: 19638292 [TBL] [Abstract][Full Text] [Related]
12. Clinical and immunological evaluation of zoledronate-activated Vgamma9gammadelta T-cell-based immunotherapy for patients with multiple myeloma. Abe Y; Muto M; Nieda M; Nakagawa Y; Nicol A; Kaneko T; Goto S; Yokokawa K; Suzuki K Exp Hematol; 2009 Aug; 37(8):956-68. PubMed ID: 19409955 [TBL] [Abstract][Full Text] [Related]
13. [The effect of MPS on LAK cell growth and its cytotoxic activity against laryngeal cancer (HEP-2)]. Wang J; Zhu X; Chen J Zhonghua Er Bi Yan Hou Ke Za Zhi; 1996; 31(5):283-6. PubMed ID: 9642362 [TBL] [Abstract][Full Text] [Related]
14. Modifying interleukin-2 concentrations during culture improves function of T cells for adoptive immunotherapy. Besser MJ; Schallmach E; Oved K; Treves AJ; Markel G; Reiter Y; Schachter J Cytotherapy; 2009; 11(2):206-17. PubMed ID: 19148842 [TBL] [Abstract][Full Text] [Related]
15. Zoledronate facilitates large-scale ex vivo expansion of functional gammadelta T cells from cancer patients for use in adoptive immunotherapy. Kondo M; Sakuta K; Noguchi A; Ariyoshi N; Sato K; Sato S; Sato K; Hosoi A; Nakajima J; Yoshida Y; Shiraishi K; Nakagawa K; Kakimi K Cytotherapy; 2008; 10(8):842-56. PubMed ID: 19016372 [TBL] [Abstract][Full Text] [Related]
16. Alloreactivity and anti-tumor activity segregate within two distinct subsets of cytokine-induced killer (CIK) cells: implications for their infusion across major HLA barriers. Sangiolo D; Martinuzzi E; Todorovic M; Vitaggio K; Vallario A; Jordaney N; Carnevale-Schianca F; Capaldi A; Geuna M; Casorzo L; Nash RA; Aglietta M; Cignetti A Int Immunol; 2008 Jul; 20(7):841-8. PubMed ID: 18469328 [TBL] [Abstract][Full Text] [Related]